Breast Cancer and Infertility

Yıl 2015, Cilt: 24 Sayı: 3, 317 - 323, 14.09.2015

Gülüzar Turan , Esra Gür

https://doi.org/10.17827/aktd.33847

Öz

Breast cancer is the most common malignancy among women and may accompany infertility. The relationship between infertility treatment and breast cancer has not yet been proven. However, estrogen exposure is well known to cause breast cancer. Recent advances in treatment options have provided young patients with breast cancer a chance of being mother

Anahtar Kelimeler

Breast cancer, infertility treatment, in vitro fertilisation

Meme Kanseri ve İnfertilite

Öz

Meme kanseri kadınlar arasında en sık izlenen kanser türü olup infertiliteye eşlik edebilir. İnfertilite tedavisi ve meme kanseri arasında henüz ispatlanmış bir ilişki yoktur. Ancak östrojen maruziyetinin meme kanserine neden olduğu iyi bilinmektedir. Bununla birlikte, son zamanlarda yeni tedavi seçenekleri meme kanseri olan genç hastalara anne olma şansını sunmuştur.

Anahtar Kelimeler

Meme kanseri, infertilite tedavisi, in vitro fertilizasyon

Kaynakça

• Siegel R, Naishadham D, Jemal A. Cancer statistics, CA Cancer J Clin. 2012;62:10–29.
• Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case- control study. Int J Cancer. 1990;46:796–800.
• Brinton LA, Scoccia B, Moghissi KS, Westhoff CL, Althuis MD, Mabie JE et al. Breast cancer risk associated with ovulation-stimulating drugs. Hum. Reprod. 2004;19:2005-13.
• Dor J, Lerner-Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril. 2002;77:324-7.
• Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2006;98:1406–15.
• Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15:17–35.
• Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000;21:427-33.
• Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. 2007;16:1400-7.
• Zreik TG, Mazloom A, Chen Y, Vannucci M, Pinnix CC, Fulton S et al. Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat. 2010;124: 13-26.
• Vlahos NF, Economopoulos KP, Fotiou S. Endometriosis, in vitro fertilization and the risk of gynaecological malignancies, including ovarian and breast cancer. Best Pract Res Clin Obstet Gynaecol. 2010;24: 39-50.
• Burkman RT, Tang MT, Malone KE, Marchbanks PA, McDonald JA, Folger SG et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women’s Contraceptive and Reproductive Experiences Study. Fertil Steril. 2003;79:844-51.
• Boukaidi SA, Cooley A, Hardy A, Matthews L, Zelivianski S, Jeruss JS. Impact of infertility regimens on breast cancer cells: follicle-stimulating hormone and luteinizing hormone lack a direct effect on breast cell proliferation in vitro. Fertil Steril. 2012;97:440-4.
• Stewart LM, Holman CD, Hart R, Bulsara MK, Preen DB, Finn JC. In vitro fertilization and breast cancer: is there cause for concern? Fertil Steril. 2012;98:334-40.
• Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M et al. SEER Cancer Statistics Review, 1975–2005. http://seer.cancer.gov/csr/1975_2005/
• Natl Cancer Inst 2008. Bethesda, MD,
• Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update. 2009;15:323-39.
• Ethics Committee of American Society for Reproductive Medicine.Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil Steril. 2013;100:1224-31.
• Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil Steril. 2006;85:277-84.
• Reddy J, Oktay K. Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril. 2012;98:1363-9.
• Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100:1673-80.
• Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update. 2009;15:323-39.
• Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer. 1990;15;65:847-50.
• Valachis A, Tsali L, Pesce LL, et al. Safety of pregnancy after primary breast carcinoma in young women: A meta-analysis to overcome bias of healthy mother effect studies. Obstet Gynecol Surv. 2010;65:786-93.
• Helewa M, Le´vesque P, Provencher D, Lea RH, Rosolowich V, Shapiro HM et al. Breast cancer, pregnancy, and breastfeeding. J Obstet Gynaecol Can. 2002;24:164–80.
• Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007;110:2222–9.
• El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer. 2006;20;6:194.
• Correspondence Address / Yazışma Adresi